The expanding Therapeutic Perspective of CCR5 Blockade
No Thumbnail Available
Date
2018-01-12
Authors
Vangelista, Luca
Vento, Sandro
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers in Immunology
Abstract
CCR5 and its interaction with chemokine ligands have been crucial for understanding
and tackling HIV-1 entry into target cells. However, over time, CCR5 has witnessed
an impressive transition from being considered rather unimportant in physiology and
pathology to becoming central in a growing number of pathophysiological conditions.
It now turns out that the massive efforts devoted to combat HIV-1 entry by interfering
with CCR5, and the subsequent production of chemokine ligand variants, small chemical
compounds, and other molecular entities and strategies, may set the therapeutic
standards for a wealth of different pathologies. Expressed on various cell types, CCR5
plays a vital role in the inflammatory response by directing cells to sites of inflammation.
Aside HIV-1, CCR5 has been implicated in other infectious diseases and non-infectious
diseases such as cancer, atherosclerosis, and inflammatory bowel disease. Individuals
carrying the CCR5Δ32 mutation live a normal life and are warranted a natural barrier to
HIV-1 infection. Therefore, CCR5 antagonism and gene-edited knockout of the receptor
gained growing interest for the therapeutic role that CCR5 blockade may play in the
attenuation of the severity or progression of numerous diseases.
Description
Keywords
CCR5, CCL5, inflammation, HIV-1, cancer
Citation
Vangelista, Luca, Vento, Sandro. (2018) The expanding Therapeutic Perspective of CCR5 Blockade. Frontiers in Immunology.